http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology<h1 class="header1">Interventional Oncology News</h1>enInterventional OncologyBIBA Medical LtdSun, 02 Aug 2015 23:25:47 -0100http://blogs.law.harvard.edu/tech/rsswebeditor@bibamedical.com3360http://www.affino.comhttp://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/learn-the-language-of-oncologyLearn the language of oncology<div style="display:block;"><div style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/learn-the-language-of-oncology"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/050/Michael_Soulen_main.jpg" border="0" hspace="5" vspace="5" /></a></div><div style="float:left;">The World Conference on Interventional Oncology (WCIO) is developing an online interventional oncology curriculum called IO University. Michael Soulen, immediate past chair of the WCIO, told Interventional News: “One of the gaps in interventional radiology training is in oncology education. The IO University is designed to address these gaps.” </div></div>Thu, 28 May 2015 11:36:00 +0000http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/learn-the-language-of-oncologyhttp://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/celonova-gets-us-fda-approval-for-clinical-trial-with-oncozeneCeloNova gets US FDA approval for clinical trial with Oncozene<div style="display:block;"><div style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/celonova-gets-us-fda-approval-for-clinical-trial-with-oncozene"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/044/Oncozene_web_-_Copy.jpg" border="0" hspace="5" vspace="5" /></a></div><div style="float:left;">CeloNova BioSciences has announced that the US FDA has granted approval to start an investigational device exemption (IDE) clinical trial for its Oncozene embolic microspheres, loaded with doxorubicin, a chemotherapy drug used in the treatment of hepatocellular carcinoma. </div></div>Fri, 14 Nov 2014 11:18:00 +0000http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/celonova-gets-us-fda-approval-for-clinical-trial-with-oncozenehttp://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/terumo-europe-to-create-an-interventional-oncology-divisionTerumo Europe to create an Interventional Oncology division<div style="display:block;"><div style="float:left;">Terumo Europe has announced the creation of an Interventional Oncology division that will be active as of 1 April 2015. The specialisation of the interventional oncology team will allow Terumo Europe to be more focused, and thus more efficient in this fast growing market, a press release from the company states. </div></div>Tue, 04 Nov 2014 09:30:00 +0000http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/terumo-europe-to-create-an-interventional-oncology-divisionhttp://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sir-spheres-recommended-in-new-oncology-clinical-guidelines-for-treatment-of-metastatic-colorectal-cancerSIR-Spheres recommended in new oncology clinical guidelines for treatment of metastatic colorectal cancer<div style="display:block;"><div style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sir-spheres-recommended-in-new-oncology-clinical-guidelines-for-treatment-of-metastatic-colorectal-cancer"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/042/Sirtex_Graphic_web.jpg" border="0" hspace="5" vspace="5" /></a></div><div style="float:left;">Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer endorse radioembolisation, specifically with yttrium-90 (Y90) resin microspheres, as a clinically proven technology to “prolong time to liver tumour progression” in patients who have failed to respond to available chemotherapy options. </div></div>Tue, 30 Sep 2014 11:13:00 +0000http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sir-spheres-recommended-in-new-oncology-clinical-guidelines-for-treatment-of-metastatic-colorectal-cancerhttp://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sirtex-expands-business-into-brazilSirtex expands business into Brazil<div style="display:block;"><div style="float:left;"><a href="http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sirtex-expands-business-into-brazil"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/015/sirtex.jpg" border="0" hspace="5" vspace="5" /></a></div><div style="float:left;">Sirtex has announced the expansion of its business in Latin America. Sirtex’s SIR-Spheres microspheres are now available to treat inoperable liver tumours in Brazil. </div></div>Tue, 09 Sep 2014 09:32:00 +0000http://www.cxvascular.com/in-interventional-oncology/in-interventional-oncology/sirtex-expands-business-into-brazil